Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver pathologies characterized by hepatic steatosis with a history of little to no alcohol consumption or secondary causes of hepatic steatosis. The prevalence of NAFLD is 20-25 % of the general population in the Western countries and is ass...
| Publicado en: | Digestive Diseases & Sciences Vol. 61; no. 5; pp. 1356 - 1365 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
May2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=114636589&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 114636589 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01632116 1VP jtl: Digestive Diseases & Sciences issn: 01632116 maglogo: N pubinfo: dt: May2016 vid: 61 iid: 5 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 114636589 114636589 NLM27017224 114636589 10.1007/s10620-016-4079-4 NLM27017224 114636589 ppf: 1356 ppct: 9 formats: tig: atl: Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. aug: au: Kaswala, Dharmesh Lai, Michelle Afdhal, Nezam Kaswala, Dharmesh H Afdhal, Nezam H affil: Liver Center, Department of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 110 Francis St #8e Boston 0221 USA sug: subj: Liver Cirrhosis Diagnosis Liver Cirrhosis Etiology Nonalcoholic Fatty Liver Disease Pathology Nonalcoholic Fatty Liver Disease Complications Liver Pathology Human Liver Liver Cirrhosis Blood Nonalcoholic Fatty Liver Disease Blood Liver Cirrhosis Pathology ab: Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver pathologies characterized by hepatic steatosis with a history of little to no alcohol consumption or secondary causes of hepatic steatosis. The prevalence of NAFLD is 20-25 % of the general population in the Western countries and is associated with metabolic risk factors such as obesity, diabetes mellitus, and dyslipidemia. The spectrum of disease ranges from simple steatosis to nonalcoholic steatohepatitis, fibrosis, and cirrhosis. Advanced fibrosis is the most significant predictor of mortality in NAFLD. It is crucial to assess for the presence and degree of hepatic fibrosis in order to make therapeutic decisions and predict clinical outcomes. Liver biopsy, the current gold standard to assess the liver fibrosis, has a number of drawbacks such as invasiveness, sampling error, cost, and inter-/intra-observer variability. There are currently available a number of noninvasive tests as an alternative to liver biopsy for fibrosis staging. These noninvasive fibrosis tests are increasingly used to rule out advanced fibrosis and help guide disease management. While these noninvasive tests perform relatively well for ruling out advanced fibrosis, they also have limitations. Understanding the strengths and limitations of liver biopsy and the noninvasive tests is necessary for deciding when to use the appropriate tests in the evaluation of patients with NAFLD. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|